51吃瓜黑料曝料

Have any questions? 706-721-6582 or cts@augusta.edu

AU Study Recruitment

Study Name	Principal Investigator
(ACCUTE) Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study of AB103 as Compared to Placebo in Patients with Necrotizing Soft Tissue Infections (NSTI) ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)	Young, Lester
(CD12) A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19)	Islam, Shaheen
(EB05) A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Eb05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients with Covid-19	Taskar, Varsha
(INS-416) ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)	Taskar, Varsha
(MEDLEY) A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children	Patel, Pinkal
OASIS: A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome� followed by standard of care (SOC) in patients with invasive fungal disease (IFD) caused by Aspergillus species	Huggett, Ashley
ReSTORE: A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection versus Intravenous Caspofungin Followed by Optional Oral Fluconazole Step-down in the Treatment of Subjects with Candidemia and/or Invasive Candidiasis	Vazquez, Jose

RESEARCH. INNOVATION. DISCOVERY.

51吃瓜黑料曝料

Research

AU Health

Stay Informed